Peptide side effects: what studies report and when to see a doctor
In short. Peptide side effects raise two different questions: what the substance itself does, and what is really in the vial. The side effects of approved medicines are known from trials. For research peptides there are few or no human data, and the content and purity of a product bought online are a risk of their own.
What "adverse event" means in a trial
Trials record every adverse event participants have, including in the placebo group. In the TRIUMPH-2 trial of retatrutide, for example, nausea was reported by 8% of those on placebo and 28% on the highest dose [6]. The drug's contribution only shows in the comparison. That is why a single experience such as "this gave me a headache" does not tell you whether the substance caused it.
The placebo effect also works the other way: expectations can produce perceived benefit. A 2026 sports medicine review highlights the placebo effect, and the way social media amplifies it, in the case of peptides [3].
What is known, group by group
| Group | What is known about harms |
|---|---|
| GLP-1-type medicines and investigational drugs (e.g. retatrutide) | Large randomised trials. Most common side effects gastrointestinal, dose-related, mostly mild to moderate. Heart rate rose with dose [5]. See retatrutide, cagrilintide side effects in trials, weight-loss drug side effects and stopping a weight-loss drug. |
| Peptides marketed for tissue healing (e.g. BPC-157, TB-500) | Animal studies reported no adverse effects, but there are no clinical safety data in humans [2]. A review says rigorous human data are scarce and there is potential for serious harm [3]. See BPC-157. |
| Growth hormone releasing peptides (and MK-677) | In a two-year MK-677 trial in older adults, appetite increased, the lower legs swelled for a while and fasting blood sugar rose [11]. The most common side effects of tesamorelin, approved in the US, are joint and muscle pain, swelling of the limbs, and redness and itching at the injection site [12]. The FDA has linked serious harms, such as a faster heart rate, to CJC-1295 [13]. The studies of ipamorelin and GHRP-6 were short, and there are no human studies of their long-term use. The side effects most often reported with sermorelin were brief facial flushing and pain at the injection site. Hexarelin and GHRP-2 raised prolactin and cortisol as well as growth hormone (sources on the substance pages). We know of no published human studies of IGF-1 LR3, and for AOD-9604 only a safety summary of six trials has been published: IGF-1 LR3: why there are no human data on harms and AOD-9604. Figures and sources on the substance pages: MK-677, tesamorelin, CJC-1295, ipamorelin, GHRP-6, GHRP-2, hexarelin and sermorelin. |
| Melanocortins (melanotan II, PT-141) | The most common side effects of PT-141 (bremelanotide), approved in the US, are nausea, flushing and headache. It raises blood pressure for a few hours and can darken the skin [14]. In the small melanotan II studies nausea was the most common side effect, and case reports have linked unsupervised use to mole changes, melanoma and prolonged erections. Sources on the substance pages: PT-141 and melanotan II. For the side effects of the approved afamelanotide implant: melanotan 1 (afamelanotide). |
| Other searched substances (GHK-Cu, NAD+, MOTS-c, LL-37) | Small studies of GHK-Cu creams reported no side effects, and even less is known about injecting it. NAD+ given into a vein caused stomach symptoms, a faster heart rate and chest tightness during the infusion [15]. The side effects of MOTS-c have not been studied in humans. LL-37 was well tolerated in wound trials but is toxic to cells at high concentrations: LL-37 and the two sides of the dose. Sources on the substance pages: GHK-Cu, NAD+ and MOTS-c. |
A risk that does not come from the substance: the product
A product bought online carries risks that no drug trial shows, because trials use the manufacturer's tested material.
- Wrong content. Fimea says an unauthorised product sold online may contain a different substance from the one on the pack [1]. In a study that tested three semaglutide vials bought without a prescription, the content deviated from the label and purity was 7.7-14.4% although the label claimed 99% [7].
- Contaminants. Endotoxin was found in all three vials [7]. Fimea says endotoxins can cause serious harm in injectable products [1].
- Infections. In the US, pharmacy-compounded sterile preparations were linked to 19 infection outbreaks and at least 1,000 cases in 2001-2013 [9].
- Dosing errors. In a poison centre case series, tenfold errors caused nausea, vomiting and abdominal pain lasting days [8]. See mixing and units.
Injection site reactions and allergy
Local reactions are a common side effect of injectable medicines. For the approved tirzepatide medicine, for example, the manufacturer lists injection site reactions and allergic reactions among common side effects [10]. For an approved medicine we know how common they are. For a research peptide we cannot tell whether redness comes from the substance, a contaminant or the injection technique, because there are no comparison data.
Three questions to ask of any side-effect claim
- Was there a comparison group? Without a placebo group you cannot tell how many would have had the same symptom anyway [6].
- How many people, for how long? Rare harms only show in large, long trials. The phase 3 TRIUMPH-2 trial of retatrutide ran for 80 weeks with 1,152 participants [6]. The human studies of BPC-157 are small pilots [2].
- Which product was studied? A trial result applies to the product used in the trial, not to a vial bought online whose content is unknown [7].
What users themselves report
Many readers want to know what other users say. We have collected forum accounts on eight topics. The pages show how many people mentioned some side effect and which side effects were mentioned: BPC-157, retatrutide, GHK-Cu, NAD+, TB-500, Semax, MOTS-c and collagen and peptides for skin.
These are individual accounts, not study results. There is no comparison group, and they cannot show whether the vial contained what the label said.
Possible risks that have not been studied
A 2026 medical journal review lists possible risks of unregulated injectables, including contamination, inaccurate dosing, pathological blood vessel growth, cancer development, cardiovascular stress and hormonal effects [4]. These are concerns based on mechanisms, not demonstrated harms. That is exactly the problem: without human studies, nobody knows.
When to seek care
- Fimea advises contacting healthcare services if you develop symptoms after using a product, and telling them what you used [1].
- If symptoms are severe or worsen quickly, go to an emergency department. In an emergency in Finland, call 112.
- Bring the pack or a photo of the label. It helps the treating doctor.
More: how to judge product quality and what regulators say.
FAQ
Are peptides safe?
There is no single answer. The side effects of approved peptide medicines are known from trials. For many research peptides, such as BPC-157, there are no clinical safety data in humans at all [2][3].
The injection site is red and itchy. Is that normal?
We cannot assess an individual symptom. Fimea advises contacting healthcare services if you develop symptoms after using a product, and telling them what you used [1]. If symptoms are severe or worsen quickly, go to an emergency department.
Do peptides raise heart rate or blood pressure?
It depends on the substance. In the phase 2 trial of retatrutide, for example, heart rate rose with dose [5]. For many research peptides there are no human measurements. A review names cardiovascular stress as one possible risk [4].
Should I tell my doctor?
Fimea's advice is to tell healthcare services what product you used if you have symptoms [1]. A doctor cannot assess symptoms properly without knowing what was taken.
How do I know whether a symptom comes from the substance?
In a single case you cannot know for sure. In trials the substance's contribution only shows in comparison with a placebo group [6]. A doctor assesses the symptom, so tell them what you have used [1].
What is known about long-term effects?
For research peptides, very little. Fimea says possible harms and long-term effects may not be known [1].
Sources
- Fimea: Fimea warns: do not use injectable peptides purchased online. 29 Jun 2026. fimea.fi
- Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PMID 40756949
- Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PMID 41966639
- Moiz A, et al. Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. Mo Med. 2026;123(4):337-343. PMID 42757290
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315
- Bellido V, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. PMID 42810372
- Ashraf AR, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription. J Med Internet Res. 2024;26:e65440. PMID 39509151
- Lambson JE, et al. Administration errors of compounded semaglutide reported to a poison control center: case series. J Am Pharm Assoc. 2023;63(5):1643-1645. PMID 37392810
- Shehab N, et al. U.S. Compounding Pharmacy-Related Outbreaks, 2001-2013. J Patient Saf. 2018;14(3):164-173. PMID 26001553
- Eli Lilly: press release, TRIUMPH-2 and TRIUMPH-3, 23 Jul 2026, with the tirzepatide (Zepbound) safety information at the end. Company release. Lilly press release (republished on Placera.se) not peer-reviewed
- Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-611. PMID 18981485
- U.S. Food and Drug Administration / DailyMed. Egrifta WR (tesamorelin), prescribing information, revised 3/2025. DailyMed
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, content current as of 22 Apr 2026. FDA
- U.S. Food and Drug Administration / DailyMed. Vyleesi (bremelanotide), prescribing information, revised 3/2024. DailyMed
- Reyna K, et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582. PMID 41704678
Sources checked in PubMed on 6 Oct 2026, the TRIUMPH-2 article on 13 Oct 2026.
Content is general information about research, not medical advice. If you have symptoms, contact a healthcare professional.